• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immediate need for next-generation and mutation-proof vaccine to protect against current emerging Omicron sublineages and future SARS-CoV-2 variants: An urgent call for researchers and vaccine companies - Correspondence.

作者信息

Chakraborty Chiranjib, Bhattacharya Manojit, Sharma Ashish Ranjan, Mohapatra Ranjan K, Chakraborty Sandip, Pal Soumen, Dhama Kuldeep

机构信息

Department of Biotechnology, School of Life Science and Biotechnology, Adamas University, Kolkata, West Bengal, 700126, India.

Department of Zoology, Fakir Mohan University, Vyasa Vihar, Balasore 756020, Odisha, India.

出版信息

Int J Surg. 2022 Oct;106:106903. doi: 10.1016/j.ijsu.2022.106903. Epub 2022 Sep 13.

DOI:10.1016/j.ijsu.2022.106903
PMID:36108909
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9467924/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e874/9467924/83bd15202328/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e874/9467924/83bd15202328/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e874/9467924/83bd15202328/gr1_lrg.jpg

相似文献

1
Immediate need for next-generation and mutation-proof vaccine to protect against current emerging Omicron sublineages and future SARS-CoV-2 variants: An urgent call for researchers and vaccine companies - Correspondence.迫切需要新一代且防突变的疫苗来抵御当前出现的奥密克戎亚谱系以及未来的新冠病毒变种：致研究人员和疫苗公司的紧急呼吁——通信
Int J Surg. 2022 Oct;106:106903. doi: 10.1016/j.ijsu.2022.106903. Epub 2022 Sep 13.
2
Omicron: Call for updated vaccines.奥密克戎：呼吁更新疫苗。
J Med Virol. 2022 Apr;94(4):1261-1263. doi: 10.1002/jmv.27530. Epub 2021 Dec 28.
3
A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice.第四针奥密克戎 RBD 疫苗加强了对 vaccinated mice 中 SARS-CoV-2 变异株（包括 BA.1 和 BA.2）的广泛中和作用。
J Med Virol. 2022 Aug;94(8):3992-3997. doi: 10.1002/jmv.27811. Epub 2022 May 6.
4
Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022.2、3 和 4 剂 COVID-19 mRNA 疫苗在 SARS-CoV-2 奥密克戎 BA.1 和 BA.2/BA.2.12.1 亚谱系占主导地位期间对免疫功能正常成年人的有效性 - VISION 网络，10 个州，2021 年 12 月至 2022 年 6 月。
MMWR Morb Mortal Wkly Rep. 2022 Jul 22;71(29):931-939. doi: 10.15585/mmwr.mm7129e1.
5
A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants.Delta-Omicron 混合 mRNA 疫苗加强针可产生针对奥密克戎和其他 SARS-CoV-2 变体的广谱中和抗体。
J Biomed Sci. 2022 Jul 7;29(1):49. doi: 10.1186/s12929-022-00830-1.
6
A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.一种糖基化 RBD 蛋白诱导针对奥密克戎和其他变体的增强型中和抗体，提高对 SARS-CoV-2 感染的保护作用。
J Virol. 2022 Sep 14;96(17):e0011822. doi: 10.1128/jvi.00118-22. Epub 2022 Aug 16.
7
A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity.含有 D614G 和 BA.1 刺突三聚体蛋白的二价疫苗或 BA.1 刺突三聚体蛋白加强针可产生广泛的中和免疫。
J Med Virol. 2022 Sep;94(9):4287-4293. doi: 10.1002/jmv.27885. Epub 2022 Jun 2.
8
Cross-variant protection against SARS-CoV-2 infection in hamsters immunized with monovalent and bivalent inactivated vaccines.用单价和双价灭活疫苗免疫的仓鼠对 SARS-CoV-2 感染的交叉变体保护作用。
Int J Biol Sci. 2022 Jul 13;18(12):4781-4791. doi: 10.7150/ijbs.72109. eCollection 2022.
9
An mRNA vaccine with broad-spectrum neutralizing protection against Omicron variant sublineages BA.4/5 -included SARS-CoV-2.一种针对包括奥密克戎变异亚谱系BA.4/5在内的新冠病毒具有广谱中和保护作用的信使核糖核酸疫苗。
Signal Transduct Target Ther. 2022 Oct 11;7(1):362. doi: 10.1038/s41392-022-01207-4.
10
Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022.COVID-19 mRNA 疫苗在奥密克戎为主导期间对免疫功能低下成年人 COVID-19 相关住院的有效性- VISION 网络，10 个州，2021 年 12 月至 2022 年 8 月。
MMWR Morb Mortal Wkly Rep. 2022 Oct 21;71(42):1335-1342. doi: 10.15585/mmwr.mm7142a4.

引用本文的文献

1
Analyzing the emerging patterns of SARS-CoV-2 Omicron subvariants for the development of next-gen vaccine: An observational study.分析严重急性呼吸综合征冠状病毒2型奥密克戎亚变体的新出现模式以开发下一代疫苗：一项观察性研究。
Health Sci Rep. 2023 Oct 18;6(10):e1596. doi: 10.1002/hsr2.1596. eCollection 2023 Oct.
2
COVID-19 vaccines and their underbelly: Are we going the right way?新冠疫苗及其潜在问题：我们走在正确的道路上吗？
Health Sci Rep. 2023 Sep 3;6(9):e1540. doi: 10.1002/hsr2.1540. eCollection 2023 Sep.
3
SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗、疫苗开发技术以及疫情期间疫苗开发的重大努力：吸取的经验教训可能有助于抗击下一次大流行。
Vaccines (Basel). 2023 Mar 17;11(3):682. doi: 10.3390/vaccines11030682.
4
Omicron subvariant BA.5 is highly contagious but containable: Successful experience from Macau.奥密克戎变异株 BA.5 传染性强但可防可控：澳门的成功经验。
Front Public Health. 2023 Jan 10;10:1029171. doi: 10.3389/fpubh.2022.1029171. eCollection 2022.
5
A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies.关于 SARS-CoV-2 奥密克戎的详细概述：其亚变体、突变和病理生理学、临床特征、免疫状况、免疫逃逸以及治疗方法。
Viruses. 2023 Jan 5;15(1):167. doi: 10.3390/v15010167.
6
Integrative Bioinformatics Approaches Indicate a Particular Pattern of Some SARS-CoV-2 and Non-SARS-CoV-2 Proteins.整合生物信息学方法揭示了一些新冠病毒和非新冠病毒蛋白质的特定模式。
Vaccines (Basel). 2022 Dec 23;11(1):38. doi: 10.3390/vaccines11010038.
7
A call for a novel and next-generation vaccine against monkeypox disease.呼吁研发针对猴痘疾病的新型下一代疫苗。
Ann Med Surg (Lond). 2022 Nov 17;84:104968. doi: 10.1016/j.amsu.2022.104968. eCollection 2022 Dec.